Resumes
Resumes
Keith Coon Phones & Addresses
-
Raleigh, NC
-
Greensboro, NC
-
2953 Old Bridgeport Way, San Diego, CA 92111
-
Scottsdale, AZ
-
Cedar Point, NC
-
Tempe, AZ
-
Greenville, NC
-
Maricopa, AZ
-
8020 Kenova St, San Diego, CA 92126
Publications
Us Patents
Treatment Of Adenocarcinoma Expressing Lkb1 With Mtor Inhibitor In Combination With Cox2 Inhibitor
View pageUS Patent:
20110091574, Apr 21, 2011
Filed:
Feb 13, 2009
Appl. No.:
12/865607
Inventors:
Landon J. Inge - Phoenx AZ, US
Keith D. Coon - San Diego CA, US
Keith D. Coon - San Diego CA, US
Assignee:
Catholic Healthcare West - Phoenix AZ
International Classification:
A61K 33/36
C12N 5/071
A61K 31/415
A61K 31/365
A61K 31/42
A61K 31/444
A61K 31/196
A61K 31/7004
A61K 31/19
A61K 31/4406
A61K 31/51
A61K 31/195
A61K 33/16
A61P 35/00
C12N 5/071
A61K 31/415
A61K 31/365
A61K 31/42
A61K 31/444
A61K 31/196
A61K 31/7004
A61K 31/19
A61K 31/4406
A61K 31/51
A61K 31/195
A61K 33/16
A61P 35/00
US Classification:
424624, 435325, 514406, 514473, 514378, 514334, 514567, 514 23, 514561, 514356, 514276, 424676
Abstract:
Methods of treating adenocarcinoma cells such as NSCLC cells are disclosed that depend upon the level of functionally active LKB1 expressed in the cancer cells being treated. In one embodiment, the cancer cells express functionally active LKB1 and the method comprises contacting those cells with a LKB1-stimulating amount of a COX-2-specific inhibitor in combination with an inhibiting amount of a specific inhibitor of mTOR. In another embodiment, the cancer cells express about 25 percent or less of the normal, functional LKB1 expressed by non-transformed cells of the same type are contacted with a growth inhibiting amount of an agent that inhibits cellular metabolism and induces energetic stress.